Download PDF
Thromb Haemost 2020; 120(01): 055-064
DOI: 10.1055/s-0039-1700516
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα

Peter van Doorn
1   Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
,
Jan Rosing
1   Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
,
Elena Campello
2   Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padua Medical School, Padua, Italy
,
Saskia Middeldorp
3   Amsterdam UMC, University of Amsterdam, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
,
Paolo Simioni
2   Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padua Medical School, Padua, Italy
,
Joost C. M. Meijers
4   Amsterdam UMC, University of Amsterdam, Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
5   Department of Molecular and Cellular Hemostasis, Sanquin, University of Amsterdam, Amsterdam, The Netherlands
,
Tilman M. Hackeng
1   Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
,
Elisabetta Castoldi
1   Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
› Author Affiliations Funding This work was supported by grant 2014–1 from the Dutch Thrombosis Foundation. J. Rosing is Van de Laar Professor of Coagulation Enzymology.
Further Information

Publication History

12 April 2019

29 August 2019

Publication Date:
08 November 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Background Factor V (FV) is proteolytically activated to FVa, which assembles with FXa in the prothrombinase complex. The C-terminus of tissue factor pathway inhibitor-α (TFPIα) inhibits both the activation and the prothrombinase activity of FV(a), but the pathophysiological relevance of this anticoagulant mechanism is unknown. FV Leiden (FVL) is less susceptible to inhibition by TFPIα, while overexpression of FV splicing variants with increased affinity for TFPIα (FV-short) causes bleeding.

Objective This study aims to develop a plasma-based assay that quantifies the susceptibility of FV(a) to inhibition by the TFPIα C-terminus.

Materials and Methods FV in highly diluted plasma was preactivated with FXa in the absence or presence of the TFPIα C-terminal peptide. After adding prothrombin, thrombin formation was monitored continuously with a chromogenic substrate and prothrombinase rates were obtained from parabolic fits of the absorbance tracings. TFPI resistance was expressed as the ratio of the prothrombinase rates with and without peptide (TFPIr).

Results The TFPIr (0.25–0.34 in 45 healthy volunteers) was independent of FV levels. The TFPIr increased from normal individuals (0.29, 95% confidence interval [CI] 0.28–0.31) to FVL heterozygotes (0.35, 95% CI 0.34–0.37) and homozygotes (0.39, 95% CI 0.37–0.40), confirming TFPI resistance of FVL. Two individuals overexpressing FV-shortAmsterdam had markedly lower TFPIr (0.16, 0.18) than a normal relative (0.29), in line with the high affinity of FV-short for TFPIα.

Conclusion We have developed and validated an assay that measures the susceptibility of plasma FV to the TFPIα C-terminus. Once automated, this assay may be used to test whether the TFPIr correlates with thrombosis or bleeding risk in population studies.

Keywords

factor V - factor V Leiden - factor V-short - prothrombinase - tissue factor pathway inhibitor

Supplementary Material

 

  • References

  • 1 Dahlbäck B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol 2016; 38 (Suppl. 01) 4-11
    CrossrefPubMedGoogle Scholar
  • 2 Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255 (01) 274-283
    CrossrefPubMedGoogle Scholar
  • 3 Zhu H, Toso R, Camire RM. Inhibitory sequences within the B-domain stabilize circulating factor V in an inactive state. J Biol Chem 2007; 282 (20) 15033-15039
    CrossrefPubMedGoogle Scholar
  • 4 Bos MHA, Camire RM. A bipartite autoinhibitory region within the B-domain suppresses function in factor V. J Biol Chem 2012; 287 (31) 26342-26351
    CrossrefPubMedGoogle Scholar
  • 5 Bunce MW, Bos MH, Krishnaswamy S, Camire RM. Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides. J Biol Chem 2013; 288 (42) 30151-30160
    CrossrefPubMedGoogle Scholar
  • 6 Suzuki K, Dahlbäck B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982; 257 (11) 6556-6564
    CrossrefPubMedGoogle Scholar
  • 7 Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry 1990; 29 (05) 1118-1128
    CrossrefPubMedGoogle Scholar
  • 8 Steen M, Dahlbäck B. Thrombin-mediated proteolysis of factor V resulting in gradual B-domain release and exposure of the factor Xa-binding site. J Biol Chem 2002; 277 (41) 38424-38430
    CrossrefPubMedGoogle Scholar
  • 9 Keller FG, Ortel TL, Quinn-Allen M-A, Kane WH. Thrombin-catalyzed activation of recombinant human factor V. Biochemistry 1995; 34 (12) 4118-4124
    CrossrefPubMedGoogle Scholar
  • 10 Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage requirements for activation of factor V by factor Xa. Eur J Biochem 1997; 247 (01) 12-20
    CrossrefPubMedGoogle Scholar
  • 11 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269 (50) 31869-31880
    CrossrefPubMedGoogle Scholar
  • 12 Nicolaes GA, Tans G, Thomassen MC. , et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270 (36) 21158-21166
    CrossrefPubMedGoogle Scholar
  • 13 Bertina RM, Koeleman BP, Koster T. , et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369 (6475): 64-67
    CrossrefPubMedGoogle Scholar
  • 14 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90 (03) 1004-1008
    CrossrefPubMedGoogle Scholar
  • 15 Broze Jr GJ, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci 2012; 17: 262-280
    CrossrefPubMedGoogle Scholar
  • 16 Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol 2016; 36 (01) 9-14
    CrossrefPubMedGoogle Scholar
  • 17 Duckers C, Simioni P, Spiezia L. , et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008; 112 (09) 3615-3623
    PubMedGoogle Scholar
  • 18 van Doorn P, Rosing J, Wielders SJ, Hackeng TM, Castoldi E. The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg1545 cleavage site. J Thromb Haemost 2017; 15 (01) 140-149
    CrossrefPubMedGoogle Scholar
  • 19 Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A 2013; 110 (44) 17838-17843
    CrossrefPubMedGoogle Scholar
  • 20 Wood JP, Petersen HH, Yu B, Wu X, Hilden I, Mast AE. TFPIα interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation. Blood Adv 2017; 1 (27) 2692-2702
    CrossrefPubMedGoogle Scholar
  • 21 Broze Jr GJ, Girard TJ. Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder. J Clin Invest 2013; 123 (09) 3710-3712
    CrossrefPubMedGoogle Scholar
  • 22 Wood JP, Ellery PER, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123 (19) 2934-2943
    CrossrefPubMedGoogle Scholar
  • 23 Camire RM. Rethinking events in the haemostatic process: role of factor V and TFPI. Haemophilia 2016; 22 (Suppl. 05) 3-8
    PubMedGoogle Scholar
  • 24 Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, Dahlbäck B. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα. J Clin Invest 2013; 123 (09) 3777-3787
    CrossrefPubMedGoogle Scholar
  • 25 Cunha ML, Bakhtiari K, Peter J, Marquart JA, Meijers JC, Middeldorp S. A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood 2015; 125 (11) 1822-1825
    CrossrefPubMedGoogle Scholar
  • 26 Wood JP, Baumann Kreuziger LM, Ellery PER, Maroney SA, Mast AE. Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state. Blood Adv 2017; 1 (06) 386-395
    CrossrefPubMedGoogle Scholar
  • 27 Omarova F, Uitte De Willige S, Ariëns RA, Rosing J, Bertina RM, Castoldi E. Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen γ′. J Thromb Haemost 2013; 11 (09) 1669-1678
    CrossrefPubMedGoogle Scholar
  • 28 Maurissen LF, Castoldi E, Simioni P, Rosing J, Hackeng TM. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost 2010; 8 (04) 750-758
    CrossrefPubMedGoogle Scholar
  • 29 Segers O, Simioni P, Tormene D. , et al. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. J Thromb Haemost 2012; 10 (01) 73-80
    CrossrefPubMedGoogle Scholar
  • 30 van Doorn P, Rosing J, Duckers C, Hackeng TM, Simioni P, Castoldi E. Factor V has anticoagulant activity in plasma in the presence of TFPIalpha: difference between FV1 and FV2. Thromb Haemost 2018; 118 (07) 1194-1202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Peraramelli S, Thomassen S, Heinzmann A. , et al. Role of exosite binding modulators in the inhibition of Fxa by TFPI. Thromb Haemost 2016; 115 (03) 580-590
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Santamaria S, Reglińska-Matveyev N, Gierula M. , et al. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation. J Biol Chem 2017; 292 (22) 9335-9344
    CrossrefPubMedGoogle Scholar
  • 33 Dahlbäck B, Guo LJ, Livaja-Koshiar R, Tran S. Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors. Res Pract Thromb Haemost 2017; 2 (01) 114-124
    PubMedGoogle Scholar
  • 34 Hoekema L, Rosing J, Tans G. An assay to quantify the two plasma isoforms of factor V. Thromb Haemost 2000; 84 (06) 1066-1071
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Schuijt TJ, Bakhtiari K, Daffre S. , et al. Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein. Circulation 2013; 128 (03) 254-266
    CrossrefPubMedGoogle Scholar